The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 12, 2021

Filed:

Nov. 13, 2017
Applicant:

Karlsson-tuner Invest As, Trondheim, NO;

Inventors:

Jan-Olof G Karlsson, Trondheim, NO;

Per Jynge, Hamar, NO;

Rolf G G Andersson, Vikingstad, SE;

Assignee:

KARLSSON-TUNER INVEST AS, Trondhein, NO;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/444 (2006.01); A61K 31/555 (2006.01); A61K 45/06 (2006.01); A61P 25/02 (2006.01); A61K 31/675 (2006.01);
U.S. Cl.
CPC ...
A61K 31/444 (2013.01); A61K 31/555 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); A61P 25/02 (2018.01);
Abstract

There is disclosed a platinum ion chelating dipyridoxyl compound according to Formula (I), or a pharmaceutically acceptable salt thereof, wherein the dipyridoxyl compound is uncoordinated or coordinated with a metal ion which is not a transition metal, for prevention or treatment of chemotherapy drug induced peripheral sensory neuropathy in a patient, wherein the chemotherapy drug comprises platinum ions. An example of such a chemotherapy drug is oxaliplatin. The drawbacks of previous metal complexed compounds containing manganese ions are eliminated. A more frequent use of the drug is possible since the problem in the prior art with accumulated manganese neurotoxicity is eliminated. The compounds can be administered both temporally and spatially separately from chemotherapy.


Find Patent Forward Citations

Loading…